Back to search

Article

Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease

2021-03-31

Abstract excerpt

Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d1a4a383-c610-5636-8770-e017a5de95a3
DOI
10.1101/2021.03.30.21254607
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel DiseaseDOI 10.1101/2021.03.30.21254607
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective StudySemantic proximity
Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine DoseSemantic proximity
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity
Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity
COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Disease on Biologic Therapies; A cross-sectional studySemantic proximity
COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity
Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel DiseaseSemantic proximity
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity
Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel DiseaseSemantic proximity
Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysisSemantic proximity
Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Semantic proximity
Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease and Platform-Inherent ChallengesSemantic proximity
Select a neighboring publication to make it the new centre.